在高生物暴露IBD患者中,优化维护IV UST的结果. 在现实世界中有效性和调整的治疗方案
Alejandro Mínguez1, Elena Coello1, Alejandro Garrido1
1IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
概括
静脉维护乌斯特基努马布有效地治疗二次性衰竭患者的炎症性肠病. 这种救援疗法是安全和有益的,特别是对于高度生物暴露的个体.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌斯特基努马布在炎症性肠道疾病中有效,但有些患者表现出二次失效.
- 对二次失效的患者进行静脉注射维护乌斯特基努马布的评估至关重要.
研究的目的:
- 评估静脉输入维护乌斯特基努马布的有效性,在患有传统乌斯特基努马布剂量二次失效的患者中.
- 评估生化标志物,药物低谷值和临床活性指数.
主要方法:
- 这是一项单一中心的回顾性研究,涉及成年患者接受静脉内维护乌斯特基努马布.
- 评估了便中calprotectin,C-反应蛋白和哈维-布拉德肖指数的减少.
- 生物缓解被定义为便calprotectin或最终水平≤250的≥80%降低,C反应蛋白<5mg/L.
主要成果:
- 包括31名患者 (77.4%是克罗恩病) 之前有过生物暴露.
- 哈维 - 布拉德肖指数,便calprotectin和C反应蛋白的显著减少.
- 48%的人实现了生物缓解;围部疾病与较低的缓解率有关.
- 在83.9%的患者中没有记录过严重的感染或恶性瘤.
结论:
- 静脉维护乌斯特基努马布是炎症性肠病的有效和安全的救援治疗方法.
- 这种策略对高度生物暴露的患者尤其有益.
- 这种方法需要进一步评估.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
324
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
324
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


